Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TherapeuticsMD ( (TXMD) ) has provided an update.
TherapeuticsMD, Inc. reported on May 12, 2026, that it generated $103,000 in net income from continuing operations for the quarter ended March 31, 2026, reversing a net loss of $636,000 a year earlier. License revenue rose to $724,000, driven mainly by the Mayne License Agreement, while total operating expenses fell 13.6% to $1.45 million, and the company ended the quarter with $8.4 million in cash and cash equivalents.
The company reiterated that it is continuing to evaluate strategic alternatives, including potential acquisitions, mergers, asset sales or other transactions, without a set timetable or assurance that any deal will be completed. The shift to positive earnings, leaner cost structure and a solid cash position may provide added flexibility as TherapeuticsMD seeks to monetize its royalty portfolio and determine its future corporate direction, outcomes that could materially affect shareholders and partners.
Spark’s Take on TXMD Stock
According to Spark, TipRanks’ AI Analyst, TXMD is a Neutral.
The score is held down primarily by weak financial fundamentals (notably the reported 2025 revenue collapse and ongoing losses), reinforced by bearish technical signals. Offsetting factors include improved cash generation and balance sheet leverage, plus a constructive corporate update showing narrowing losses and growing royalty/license revenue, but valuation support is limited at a ~20.6 P/E with no dividend.
To see Spark’s full report on TXMD stock, click here.
More about TherapeuticsMD
TherapeuticsMD, Inc., now a pharmaceutical royalty company listed on Nasdaq as TXMD, previously operated as a women’s healthcare firm focused on products spanning pregnancy prevention through menopause. Since changing its business model in December 2022, the company has exited research, development and commercial operations and now primarily collects royalties from licensees of its former women’s health products.
Average Trading Volume: 23,224
Technical Sentiment Signal: Hold
Current Market Cap: $22.92M
For an in-depth examination of TXMD stock, go to TipRanks’ Overview page.